This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q61.2 (autosomal dominant polycystic kidney disease) | Special Copayment Reduction: V264 |
| B. Synonyms | Polycystic kidney, autosomal dominant |
| C. Adult onset | Likelihood of first onset in adulthood: high — ADPKD is an adult-onset rare kidney disease typically first diagnosed in the 30s~50s with hypertension, flank pain, hematuria, recurrent urinary tract infections, abdominal distension, and so on. In some, kidney cysts are found incidentally. End-stage renal disease is reached at an average age of about 54~58 years. |
| 1. History | 1899 description by Steiner → 1985 identification of the PKD1 locus → 1994 cloning of PKD1 → 1996 PKD2 → 2018 domestic approval of tolvaptan. |
| 2. Causes | Pathogenic variants in PKD1 (16p13.3) or PKD2 (4q22.1); loss of function of the polycystin-1/2 complex; 'two-hit' hypothesis. |
| 3. Genetics | PKD1 (about 78%): polycystin-1, 4,303 amino acids. PKD2 (about 15%): polycystin-2 (TRPP2), 968 amino acids. Autosomal dominant; heterozygosity alone causes disease. Faster progression with PKD1 variants. |
| 4. General epidemiology | 1 in 400~1,000 births (the most common monogenic kidney disease); all ethnic groups; about 5~10% of all dialysis patients. |
| 5. Pathophysiology | Somatic mutation via the two-hit mechanism → loss of polycystin function → mTOR and cAMP overactivation → cyst epithelial proliferation and intracystic secretion → cyst expansion. |
| 6. Symptoms | Hypertension, flank and abdominal pain, hematuria, recurrent urinary tract infections, kidney stones, abdominal distension. Liver cysts (asymptomatic to abdominal distension). Rupture of intracranial aneurysm (subarachnoid hemorrhage). |
| 7. Signs | Palpable bilateral kidney enlargement, hepatomegaly, hypertension, proteinuria, hematuria; bilateral multiple cysts on MRI; intracranial aneurysms. |
| 8. Screening | Abdominal ultrasound screening in adults with a family history (Ravine criteria); infants and children tested when symptomatic; genetic testing (atypical cases). |
| 9. Diagnosis | Abdominal ultrasound (Ravine/Pei criteria), kidney MRI (total kidney volume measurement, htTKV calculation), PKD1 and PKD2 genetic testing. |
| 10. Treatment | Tolvaptan (V2 receptor antagonist, inhibits cyst growth); RAAS blockade (hypertension, renal protection); symptom management; renal replacement therapy and transplantation. |
| 11. Prognosis | PKD1: ESRD at mean age 54; PKD2: ESRD at mean age 74; rupture of intracranial aneurysm is one of the major causes of death; tolvaptan reduces the rate of GFR decline by about 26%. |
| 12. Prevention | Genetic counseling, PGT; strict blood pressure control; screening MRA for intracranial aneurysms in families; early initiation of tolvaptan to protect renal function. |
| 13. References | Torres VE et al., NEJM 2012 (TEMPO 3:4); Grantham JJ et al., NEJM 2006; Chapman AB et al., CJASN 2015, and 7 others |
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common monogenic kidney disease, in which multiple cysts progressively develop and enlarge in both kidneys, leading to renal failure. The first descriptions of familial kidney cysts date back to the 16th century, and in 1899 Steiner of Germany clinically clearly described a familially transmitted cystic kidney disease. In 1957, Robson and Lego established that the disease is inherited in an autosomal dominant manner.
With advances in genetics, in 1985 Reeders et al. confirmed by linkage analysis that the main causative gene locus of ADPKD is located on the short arm of chromosome 16 (16p13.3) (later named PKD1). In 1993, a European research team identified a second causative gene locus on chromosome 4 (PKD2), and in 1994 the European PKD Consortium cloned the PKD1 gene and identified its product, polycystin-1 (PC1). In 1996, Mochizuki et al. identified the PKD2 gene and its product, polycystin-2 (PC2, TRPP2).
Since the 2000s, it has been revealed that the polycystin complex is located in the primary cilia of renal tubular epithelial cells, senses mechanical and chemical signals, and regulates intracellular calcium and cAMP signaling. This became decisive evidence for reclassifying ADPKD as a ciliopathy. In 2006, the CRISP (Consortium for Radiologic Imaging Studies of Polycystic Kidney) study by Grantham et al. established total kidney volume (TKV) as an imaging biomarker predicting the prognosis of ADPKD.
The biggest turning point in the history of treatment was the 2012 TEMPO 3:4 clinical trial (Torres et al.), which demonstrated that tolvaptan—a V2 vasopressin receptor antagonist—reduced the increase in TKV by about 50% and slowed the rate of GFR decline by about 26% in patients with ADPKD. In 2018, the FDA and EMA approved tolvaptan for adults with ADPKD at high risk of progression to renal failure, and in Korea it has also been covered by insurance since 2018. Recently, research on various targeted therapies such as mTOR inhibitors, somatostatin analogs, metformin, and veretamoxomab is under way.
In Korea, ADPKD is registered under the rare disease special copayment reduction code V264 and is an important rare kidney disease accounting for about 5~8% of all dialysis patients. Nephrology and a multidisciplinary team collaborate to systematically manage blood pressure control, inhibition of cyst growth (tolvaptan), management of complications (intracranial aneurysms, liver cysts), and kidney transplant planning.
ADPKD is an autosomal dominant genetic disease caused by a pathogenic variant in one of two causative genes. PKD1 (16p13.3) variants account for about 78% of the total and PKD2 (4q22.1) variants for about 15%, and the remaining about 7% have no identified causative gene (possibly undiscovered genes such as ADPKD3 and beyond) or de novo variants.
PKD1 gene and polycystin-1: the PKD1 gene is located on the short arm of chromosome 16 (16p13.3), is about 52 kb in size, and consists of 46 exons. Six pseudogenes similar to PKD1 exist in the genome, making genetic analysis technically difficult. The product of PKD1, polycystin-1 (PC1), is a large membrane protein of 4,303 amino acids with numerous ligand-binding motifs in its extracellular domain (leucine-rich repeats, lectin-like domain, REJ domain, etc.). PC1 forms a complex with polycystin-2 (PC2) in the primary cilia of renal tubular epithelial cells, senses mechanical stimuli (flow) and chemical stimuli, and regulates intracellular calcium influx and downstream signal transduction.
PKD2 gene and polycystin-2: the PKD2 gene is located on the long arm of chromosome 4 (4q22.1) and consists of 15 exons. Its product, polycystin-2 (PC2, TRPP2), is a calcium-permeable nonselective cation channel of 968 amino acids expressed in the endoplasmic reticulum (ER) and primary cilia. PC2 binds the C-terminus of PC1 to form a mechanosensory complex and plays a key role in maintaining intracellular calcium homeostasis.
Two-hit hypothesis: although ADPKD is autosomal dominant, cysts do not develop throughout all heterozygous carriers. Cysts arise only in cells in which an acquired mutation of the second allele (two-hit) has occurred at the somatic level. That is, against the background of a germline heterozygous PKD1 or PKD2 variant, when a somatic mutation occurs in the remaining normal allele in a single renal tubular epithelial cell, polycystin function is completely lost in that cell and cystic transformation begins. This two-hit mechanism explains why the number of cysts in ADPKD increases with age and why cyst distribution varies within individuals and between families.
Patients with PKD1 variants reach ESRD about 20 years earlier than patients with PKD2 variants (mean age 54 vs. 74), suggesting that PC1 function is more strongly involved in suppressing cyst formation than PC2. Even within PKD1, truncating variants are associated with faster progression than non-truncating (missense) variants.
ADPKD is an autosomal dominant genetic disease, and the disease manifests in the heterozygous state (variant in only one allele). If one parent has ADPKD, the disease develops in 50% of the children. Where there is no family history, about 5~10% arise from de novo variants.
PKD1 gene (16p13.3): 52 kb, 46 exons, 12.9 kb mRNA, 4,303-amino-acid PC1. Six highly similar pseudogenes in the genome (pseudogenes PKD1P1~PKD1P6) share high homology across exons 1~33, making variant detection difficult without long-range PCR or long-read sequencing. To date, more than about 1,800 pathogenic variants have been registered in LOVD (Leiden Open Variation Database). Truncating variants (nonsense, frameshift, splicing) are associated with faster clinical progression than non-truncating (missense) variants.
PKD2 gene (4q22.1): 68 kb, 15 exons, 5.4 kb mRNA, 968-amino-acid PC2. Patients with PKD2 variants on average reach ESRD about 20 years later than patients with PKD1 variants, and the clinical course is milder. To date, more than about 200 pathogenic variants have been reported.
Genotype-phenotype correlation: clinical severity decreases in the order PKD1 truncating variants > PKD1 non-truncating variants > PKD2 variants. However, the clinical spectrum is wide even within the same family, and additional modifier genes and environmental factors are understood to influence the phenotype. In particular, GANAB (α-glucosidase II α subunit) variants have recently been reported as a cause of atypical ADPKD causing a mild renal phenotype and prominent liver cysts.
Clinical application of genetic testing: PKD1/PKD2 genetic testing is performed ① when imaging findings are atypical or there is no family history, ② in high-risk family members being evaluated for kidney donation, ③ for preimplantation genetic testing (PGT) and prenatal diagnosis, and ④ when required for enrollment in clinical research. When the diagnosis is clear by imaging criteria (Ravine/Pei criteria), genetic testing is not necessarily required. Next-generation sequencing (NGS)-based panel testing and long-read sequencing to distinguish pseudogenes are the current diagnostic standard.
ADPKD occurs worldwide at a frequency of about 1 in 400~1,000 births and is the most common monogenic kidney disease. This prevalence is the highest among all polycystic kidney diseases, and there are estimated to be more than about 12.5 million~15 million patients worldwide. ADPKD is the fourth leading cause of end-stage renal disease, accounting for about 5~10% of all dialysis patients.
There is no sex difference, and it occurs in all ethnic groups and regions. The age of onset is typically the 30s~50s, but hypertension or kidney cysts are sometimes found in childhood. With a family history, early detection is possible by imaging. Some patients are asymptomatic and are found incidentally on imaging performed for other reasons.
Epidemiology in Korea: the prevalence of ADPKD in Korea is estimated at about 1 in 1,000, accounting for about 5~8% of dialysis patients in Korea. Based on Health Insurance Review & Assessment Service (HIRA) data, about 15,000~20,000 patients diagnosed with ADPKD are estimated to be registered as of the 2020s. Through special copayment reduction V264 registration, they receive copayment reduction benefits for 5 years. Recently, with insurance coverage of tolvaptan, the number of patients receiving treatment to slow progression of renal failure has been increasing.
Natural history: total kidney volume (TKV) in patients with ADPKD increases by about 5~6% per year, and the rate of GFR decline averages about 4.4~5.9 mL/min/1.73m²/year. Patients with PKD1 variants reach ESRD at a mean age of 54, and patients with PKD2 variants at a mean age of 74. Liver cysts develop in about 80~94% of patients with ADPKD and are generally asymptomatic, but in some (especially women, multiparous) massive polycystic liver disease causes abdominal distension and pain. Intracranial aneurysms occur in about 5~10% of patients with ADPKD (increased compared with about 2~3% of the general population), and rupture causes death or serious disability from subarachnoid hemorrhage.
The core of the pathophysiology of ADPKD is loss of polycystin function via the two-hit mechanism, which causes abnormal proliferation of tubular epithelial cells, intracystic fluid secretion, and extracellular matrix changes, resulting in cyst formation and expansion.
Normal function of the polycystin complex: the PC1-PC2 complex is located in the primary cilia of renal tubular epithelial cells and senses intratubular flow (mechanical flow). On flow stimulation, calcium enters from outside the cell through the PC2 channel, and this calcium signal triggers additional calcium release from the endoplasmic reticulum (CICR, calcium-induced calcium release), raising the intracellular calcium concentration. The increase in intracellular calcium inhibits the mTOR and cAMP pathways, regulating cell proliferation.
Mechanism of cyst formation: in cells in which PC1 or PC2 has been completely lost through two hits, intracellular calcium decreases, which activates adenylyl cyclase and increases cAMP. Increased cAMP activates the B-Raf/MEK/ERK pathway and the mTOR/S6K pathway, promoting cell proliferation. At the same time, cAMP activates CFTR and other chloride channels facing the cyst lumen, so chloride and water are secreted into the cyst and the cyst expands. mTOR activation further accelerates cell growth and proliferation. Changes in the extracellular matrix (ECM) around the cyst (MMP activation, fibronectin and collagen changes) also contribute to cyst growth.
Mechanism of renal function decline: progressively enlarging cysts replace the renal parenchyma and compress normal tubules, and interstitial fibrosis and inflammation progress. Cyst infection (intracystic bacterial infection) and intracystic hemorrhage also aggravate local tissue damage. Hypertension (RAAS overactivation) causes glomerular hypertension, accelerating GFR decline. As a result, renal function gradually declines, reaching ESRD over decades.
Mechanisms of extrarenal complications: liver cysts arise by the same mechanism in intrahepatic bile duct epithelial cells, and PC1/PC2 are also expressed in the cilia of bile duct epithelial cells. Intracranial aneurysms are associated with extracellular matrix abnormalities of the vessel wall in ADPKD (PC1 is also expressed in vascular smooth muscle). Cardiac valve abnormalities (mitral valve prolapse, etc.) are also reported at a higher frequency in ADPKD than in the general population.
Symptoms of ADPKD appear mainly in adults in their 30s~50s and are divided into renal and extrarenal symptoms.
Renal symptoms: hypertension is the most common early symptom, and about 60~70% of patients with ADPKD experience hypertension before ESRD. When cysts compress the renal parenchyma, local ischemia activates the RAAS, increasing renin secretion and causing hypertension. Flank and abdominal pain is caused by cyst expansion, intracystic hemorrhage (intracystic hemorrhage causes hematuria and acute pain), cyst infection, kidney stones, and so on. Hematuria appears as both gross bleeding (with hematuria or flank pain due to cyst rupture) and microscopic hematuria. Recurrent urinary tract infections arise from bacterial colonization within cysts, and cyst infections, accompanied by fever and pain, sometimes respond poorly to antibiotic treatment. Kidney stones occur in about 20% of patients with ADPKD (uric acid or calcium oxalate) and cause stone pain and hematuria. Abdominal distension is due to kidney enlargement and liver cysts and is prominent in advanced patients.
Liver cysts: liver cysts develop in about 80~94% of patients with ADPKD, but most are asymptomatic. In some (especially multiparous women), polycystic liver disease (PLD) causes abdominal distension, pain, early satiety, and dyspnea. Liver function is mostly maintained as normal.
Intracranial aneurysms: these occur in about 5~10% of patients with ADPKD, and more often with a family history. Most are asymptomatic, but on rupture, subarachnoid hemorrhage occurs, presenting with sudden severe headache ('thunderclap headache'), loss of consciousness, nausea, and neck stiffness. This is one of the most serious acute complications of ADPKD.
Other symptoms: cardiac valve abnormalities (mitral valve prolapse, etc.), hernias (abdominal wall hernia, inguinal hernia; due to increased intra-abdominal pressure), seminal vesicle cysts (men; a rare cause of infertility), and arachnoid cysts (asymptomatic or headache) may also be present.
Abdominal findings: both kidneys are palpable as lumpy masses on both sides of the abdomen, and in advanced patients the kidneys are enlarged to the point of occupying most of the abdomen. Hepatomegaly may accompany due to liver cysts. When abdominal distension is severe, differentiation from ascites is needed.
Blood pressure: hypertension is common, and hypertension often precedes in other ADPKD patients in the family as well.
Laboratory findings: elevated serum creatinine, decreased GFR, proteinuria (microproteinuria or overt proteinuria), and hematuria (gross or microscopic) appear. Anemia appears as renal failure progresses, but in patients with ADPKD, erythropoietin secretion is relatively preserved, so there may be less anemia in early renal failure. Elevated uric acid is associated with reduced renal excretion.
Imaging findings: multiple cysts in both kidneys on abdominal ultrasound are characteristic. Age-based diagnostic criteria (Pei criteria: 3 or more at 15~39 years, 2 or more at 40~59 years, 4 or more at 60 years and older) are used. MRI is the optimal method for measuring total kidney volume (TKV) and height-adjusted total kidney volume (htTKV, height-adjusted TKV), and htTKV of 245 mL/m or more is used for the tolvaptan indication as the Mayo class 1C or higher criterion suggesting rapid progression. Intracranial MR angiography (MRA) is used to screen for intracranial aneurysms.
Universal general population screening for ADPKD is not performed. Screening of at-risk groups based on family history is key.
Adults with a family history: when one parent has ADPKD, the child has a 50% risk. Checking for cysts by abdominal ultrasound (age-based Pei/Ravine criteria) is the first-line screening method. Even if ultrasound is negative, cysts may not yet have developed at a young age, so a negative result before age 30 has low reliability for exclusion. A negative ultrasound at age 40 or older has high reliability for excluding ADPKD.
Kidney donor evaluation: in adults considering living kidney donation within the family, ADPKD status must be accurately evaluated. When ultrasound alone is insufficient, MRI or genetic testing is performed.
Screening for intracranial aneurysms: in ADPKD patients and families with a family history of intracranial aneurysm, screening using intracranial MRA is recommended (around age 20 after ADPKD diagnosis, or after diagnosis of an aneurysm in the family). When an asymptomatic aneurysm is found, the treatment decision is made in consultation with a neurosurgeon or interventional neuroradiologist, depending on its size and location.
Pediatric screening: routine ultrasound screening of children with one parent with ADPKD is not recommended by most guidelines. Ultrasound is performed when there are symptoms such as hypertension, hematuria, or proteinuria. This is because early detection does not greatly change treatment, and disclosure can impose psychological and insurance burdens.
Diagnosis of ADPKD is made through imaging criteria and genetic testing.
Abdominal ultrasound diagnostic criteria (Pei 2009 modified criteria): with a family history, the diagnosis can be made when age-specific cyst number criteria are met on ultrasound. 15~39 years: 3 or more in both kidneys combined; 40~59 years: 2 or more in each kidney; 60 years and older: 4 or more in each kidney. Without a family history, diagnosis is approached more cautiously and genetic testing is considered.
Kidney MRI: precisely measures the number and size of cysts, total kidney volume (TKV), and height-adjusted total kidney volume (htTKV). htTKV is essential for evaluating the tolvaptan indication (Mayo Imaging Classification, 1C~1E: htTKV 245 mL/m or more, age-adjusted) and for monitoring progression. On T2-weighted images, cysts appear hyperintense (bright), and it is also useful for differentiating infected and hemorrhagic cysts.
Genetic testing: PKD1/PKD2 gene panel NGS or whole exome analysis. Long-read sequencing (PacBio, Oxford Nanopore) may be needed to distinguish PKD1 pseudogenes. The positivity rate of genetic testing in clinically diagnosed ADPKD is about 90%. Genetic testing is performed for atypical findings, kidney donor evaluation, and when PGT or prenatal diagnosis is needed.
Renal function assessment: serum creatinine, eGFR (CKD-EPI equation), proteinuria (spot ACR or 24-hour urine), hematuria, and blood pressure are monitored regularly. Tracking the rate of GFR decline is important for assessing treatment effect and prognosis.
Treatment of ADPKD consists of inhibition of cyst growth, management of complications, renal protection, and renal replacement therapy.
Tolvaptan (Jinarc/Samsca): a V2 vasopressin receptor antagonist that inhibits cyst growth by blocking vasopressin-induced cAMP production in the collecting duct. In the TEMPO 3:4 study (Torres et al., 2012), it reduced the increase in TKV by about 50% and slowed the rate of GFR decline by about 26%. In the REPRISE study (Torres et al., 2017), it reduced the rate of GFR decline by about 35%. Indication: adult ADPKD patients with Mayo class 1C or higher (htTKV 245 mL/m or more) or at risk of rapid progression. Main adverse effects: polyuria (aquaretic effect), thirst, nocturia; hepatotoxicity (ALT elevation in about 1~2%, rarely serious liver injury) is the most important precaution, and liver function monitoring every 2 months is mandatory. Covered by National Health Insurance in Korea since 2018.
RAAS blockers: ACE inhibitors or angiotensin receptor blockers are used as first-line agents for blood pressure control and renal protection. The HALT-PKD study confirmed that strict blood pressure control (target 95/65 mmHg or lower) significantly reduced the increase in TKV.
Lifestyle management: there is evidence that adequate fluid intake (3L or more per day) can suppress ADH secretion and slow cyst growth. A low-salt diet (6g/day or less) is important for blood pressure control and renal protection. Caffeine can increase cAMP, so reducing excessive intake is recommended. Regular exercise helps with blood pressure control and overall health.
Treatment of complications: for cyst infection, lipid-soluble antibiotics (fluoroquinolones, trimethoprim-sulfamethoxazole) have excellent penetration into cysts. Intracystic hemorrhage is mostly treated conservatively (bed rest, hydration, analgesics). Kidney stones are treated, depending on type, with extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy, or medication (allopurinol for uric acid stones). For intracranial aneurysms, neurosurgical clipping or endovascular coil embolization is decided according to size (7mm or more), location, and growth rate. When symptoms of massive polycystic liver disease are severe, percutaneous cyst aspiration-sclerotherapy, surgical cyst resection, or liver transplantation is considered.
Renal replacement therapy and transplantation: on reaching ESRD, hemodialysis or peritoneal dialysis is started, and kidney transplantation is thereafter the preferred treatment. Kidney transplant outcomes in ADPKD are similar to or better than those of renal failure from other causes. Pre-transplant nephrectomy is performed when the kidneys are so large that placing the transplanted kidney is difficult.
ADPKD is a slowly progressive disease, and a relatively good long-term prognosis can be expected with appropriate management.
Renal prognosis: the mean age at reaching ESRD is about 54 years for patients with PKD1 variants and about 74 years for patients with PKD2 variants. Faster progression is observed in patients with truncating PKD1 variants. Tolvaptan treatment has been confirmed to slow the rate of GFR decline by about 26~35%, corresponding to a delay of dialysis by about 2~3 years. Strict control of hypertension is also important for preserving renal function.
Causes of death: the main causes of death in patients with ADPKD are cardiovascular disease (hypertension-related), complications of renal failure, and rupture of intracranial aneurysms. Intracranial aneurysms are an important cause of death before age 40 in patients with ADPKD, and early screening and appropriate treatment are important for prevention.
Quality of life: in the early stage when renal function is preserved, quality of life is relatively good, but abdominal distension, pain, recurrent hematuria, and recurrent urinary tract infections are causes of persistent discomfort. The polyuria and nocturia adverse effects of tolvaptan also affect quality of life.
Follow-up: renal function (eGFR, proteinuria, blood pressure), kidney MRI (TKV tracking, every 2 years), intracranial MRA (every 3~5 years after the initial evaluation), liver function monitoring in patients taking tolvaptan (every 2 months), liver cyst status, and cardiac valve echocardiography (when a valve abnormality is suspected) are evaluated regularly. Ongoing management at an ADPKD specialty clinic or rare disease specialty center is recommended.
Primary prevention of ADPKD is achieved through genetic counseling and PGT. When an ADPKD patient or spouse is an ADPKD carrier, it is possible to select out affected embryos before implantation using PGT. Genetic risks and options are fully discussed through genetic counseling.
Secondary prevention — early detection and slowing of progression: early diagnosis by regular ultrasound screening in adults with a family history. After early diagnosis, blood pressure is strictly controlled (target 110~130/70~80 mmHg), and the decision to start tolvaptan treatment is made through assessment of the risk of rapid progression (Mayo classification). Adequate fluid intake, a low-salt diet, caffeine restriction, and regular exercise are lifestyle prevention strategies. Asymptomatic aneurysms are detected early through screening MRA for intracranial aneurysms, and treatment decisions are made.
Tertiary prevention — prevention of complications: early detection and treatment of urinary tract infections, prevention of kidney stones (adequate fluid intake, low-salt diet, potassium citrate), prompt antibiotic treatment of cyst infections, and regular follow-up of intracranial aneurysms (MRA every 3~5 years) are key to preventing complications. Avoiding nephrotoxic drugs (NSAIDs, minimizing contrast media, aminoglycosides) to preserve renal function is also important. To avoid missing the right time for kidney transplantation, transplant preparation begins at an eGFR level of 15~20.